Búsqueda | Portal Regional de la BVS

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study.

Ait-Khaled, Mounir; Oyee, James; Ooi, Adrian Yit Reen; Wynne, Brian; Maldonado, Andres; Jones, Bryn; Wang, Tao.

Open Forum Infect Dis ; 11(5): ofae227, 2024 May.

Artículo en Inglés | MEDLINE | ID: mdl-38737429

RESUMEN

TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)-based regimens. In this post hoc subgroup analysis, 144-week efficacy and tolerability of dolutegravir/lamivudine in participants who switched from elvitegravir/cobicistat/emtricitabine/TAF were consistent with the overall switch population. Clinical Trials Registration: NCT03446573.

RESUMEN

ENVIAR RESULTADO:

SELECCIÓN DE REFERENCIAS

DETALLE DE LA BÚSQUEDA